Effects of gender on relapse prevention in smokers treated with bupropion SR

David Gonzales, Wendy Bjornson, Michael J. Durcan, Jonathan D. White, J. Andrew Johnston, A. Sonia Buist, David P L Sachs, Nancy A. Rigotti, Raymond Niaura, James Taylor Hays, Richard D. Hurt

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background: Recent data suggest that women smokers respond differently than men to cessation pharmacotherapies, particularly nicotine replacement therapy (NRT). Lower abstinence and higher relapse rates are often reported for women treated with NRT. Gender effects for those treated with non-nicotinic, bupropion-hydrochloride sustained release for relapse prevention have not been studied. Methods: Data from a multicenter relapse-prevention (RP) trial of bupropion (November 1995-June 1998) were analyzed for gender differences. Men and women smokers (N=784) were treated with open-label bupropion for 7 weeks. Those abstinent at Week 7 (n=432) were enrolled in the double-blind relapse-prevention phase and randomized to placebo or continued bupropion for 45 additional weeks. Results: Differences in point-prevalence abstinence rates between men (61.8%) and women (55.6%) in open-label bupropion (Week 7) were not significant. In the RP-phase Week 52, continuous abstinence rates for men and women were 37.8% and 36.4% (bupropion) and 36.6% and 29.9% (placebo), respectively; point-prevalence abstinence rates for men and women were 54.1% and 55.9% (bupropion) and 42.9% and 41.3% (placebo), respectively. Abstinence rates and time to relapse were superior for both men and women who received longer treatment. Gender differences within treatment groups were not significant. Median time to relapse was equal for men and women within each treatment group: Week 32 for bupropion and Week 20 for placebo.Conclusions: Our data suggest that bupropion is a promising pharmacotherapy for preventing relapse, particularly for women.

Original languageEnglish (US)
Pages (from-to)234-239
Number of pages6
JournalAmerican Journal of Preventive Medicine
Volume22
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Bupropion
Secondary Prevention
Placebos
Recurrence
Nicotine
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health

Cite this

Gonzales, D., Bjornson, W., Durcan, M. J., White, J. D., Johnston, J. A., Buist, A. S., ... Hurt, R. D. (2002). Effects of gender on relapse prevention in smokers treated with bupropion SR. American Journal of Preventive Medicine, 22(4), 234-239. https://doi.org/10.1016/S0749-3797(02)00419-1

Effects of gender on relapse prevention in smokers treated with bupropion SR. / Gonzales, David; Bjornson, Wendy; Durcan, Michael J.; White, Jonathan D.; Johnston, J. Andrew; Buist, A. Sonia; Sachs, David P L; Rigotti, Nancy A.; Niaura, Raymond; Hays, James Taylor; Hurt, Richard D.

In: American Journal of Preventive Medicine, Vol. 22, No. 4, 2002, p. 234-239.

Research output: Contribution to journalArticle

Gonzales, D, Bjornson, W, Durcan, MJ, White, JD, Johnston, JA, Buist, AS, Sachs, DPL, Rigotti, NA, Niaura, R, Hays, JT & Hurt, RD 2002, 'Effects of gender on relapse prevention in smokers treated with bupropion SR', American Journal of Preventive Medicine, vol. 22, no. 4, pp. 234-239. https://doi.org/10.1016/S0749-3797(02)00419-1
Gonzales, David ; Bjornson, Wendy ; Durcan, Michael J. ; White, Jonathan D. ; Johnston, J. Andrew ; Buist, A. Sonia ; Sachs, David P L ; Rigotti, Nancy A. ; Niaura, Raymond ; Hays, James Taylor ; Hurt, Richard D. / Effects of gender on relapse prevention in smokers treated with bupropion SR. In: American Journal of Preventive Medicine. 2002 ; Vol. 22, No. 4. pp. 234-239.
@article{728432e9f9f8486194ad9b526b296835,
title = "Effects of gender on relapse prevention in smokers treated with bupropion SR",
abstract = "Background: Recent data suggest that women smokers respond differently than men to cessation pharmacotherapies, particularly nicotine replacement therapy (NRT). Lower abstinence and higher relapse rates are often reported for women treated with NRT. Gender effects for those treated with non-nicotinic, bupropion-hydrochloride sustained release for relapse prevention have not been studied. Methods: Data from a multicenter relapse-prevention (RP) trial of bupropion (November 1995-June 1998) were analyzed for gender differences. Men and women smokers (N=784) were treated with open-label bupropion for 7 weeks. Those abstinent at Week 7 (n=432) were enrolled in the double-blind relapse-prevention phase and randomized to placebo or continued bupropion for 45 additional weeks. Results: Differences in point-prevalence abstinence rates between men (61.8{\%}) and women (55.6{\%}) in open-label bupropion (Week 7) were not significant. In the RP-phase Week 52, continuous abstinence rates for men and women were 37.8{\%} and 36.4{\%} (bupropion) and 36.6{\%} and 29.9{\%} (placebo), respectively; point-prevalence abstinence rates for men and women were 54.1{\%} and 55.9{\%} (bupropion) and 42.9{\%} and 41.3{\%} (placebo), respectively. Abstinence rates and time to relapse were superior for both men and women who received longer treatment. Gender differences within treatment groups were not significant. Median time to relapse was equal for men and women within each treatment group: Week 32 for bupropion and Week 20 for placebo.Conclusions: Our data suggest that bupropion is a promising pharmacotherapy for preventing relapse, particularly for women.",
author = "David Gonzales and Wendy Bjornson and Durcan, {Michael J.} and White, {Jonathan D.} and Johnston, {J. Andrew} and Buist, {A. Sonia} and Sachs, {David P L} and Rigotti, {Nancy A.} and Raymond Niaura and Hays, {James Taylor} and Hurt, {Richard D.}",
year = "2002",
doi = "10.1016/S0749-3797(02)00419-1",
language = "English (US)",
volume = "22",
pages = "234--239",
journal = "American Journal of Preventive Medicine",
issn = "0749-3797",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of gender on relapse prevention in smokers treated with bupropion SR

AU - Gonzales, David

AU - Bjornson, Wendy

AU - Durcan, Michael J.

AU - White, Jonathan D.

AU - Johnston, J. Andrew

AU - Buist, A. Sonia

AU - Sachs, David P L

AU - Rigotti, Nancy A.

AU - Niaura, Raymond

AU - Hays, James Taylor

AU - Hurt, Richard D.

PY - 2002

Y1 - 2002

N2 - Background: Recent data suggest that women smokers respond differently than men to cessation pharmacotherapies, particularly nicotine replacement therapy (NRT). Lower abstinence and higher relapse rates are often reported for women treated with NRT. Gender effects for those treated with non-nicotinic, bupropion-hydrochloride sustained release for relapse prevention have not been studied. Methods: Data from a multicenter relapse-prevention (RP) trial of bupropion (November 1995-June 1998) were analyzed for gender differences. Men and women smokers (N=784) were treated with open-label bupropion for 7 weeks. Those abstinent at Week 7 (n=432) were enrolled in the double-blind relapse-prevention phase and randomized to placebo or continued bupropion for 45 additional weeks. Results: Differences in point-prevalence abstinence rates between men (61.8%) and women (55.6%) in open-label bupropion (Week 7) were not significant. In the RP-phase Week 52, continuous abstinence rates for men and women were 37.8% and 36.4% (bupropion) and 36.6% and 29.9% (placebo), respectively; point-prevalence abstinence rates for men and women were 54.1% and 55.9% (bupropion) and 42.9% and 41.3% (placebo), respectively. Abstinence rates and time to relapse were superior for both men and women who received longer treatment. Gender differences within treatment groups were not significant. Median time to relapse was equal for men and women within each treatment group: Week 32 for bupropion and Week 20 for placebo.Conclusions: Our data suggest that bupropion is a promising pharmacotherapy for preventing relapse, particularly for women.

AB - Background: Recent data suggest that women smokers respond differently than men to cessation pharmacotherapies, particularly nicotine replacement therapy (NRT). Lower abstinence and higher relapse rates are often reported for women treated with NRT. Gender effects for those treated with non-nicotinic, bupropion-hydrochloride sustained release for relapse prevention have not been studied. Methods: Data from a multicenter relapse-prevention (RP) trial of bupropion (November 1995-June 1998) were analyzed for gender differences. Men and women smokers (N=784) were treated with open-label bupropion for 7 weeks. Those abstinent at Week 7 (n=432) were enrolled in the double-blind relapse-prevention phase and randomized to placebo or continued bupropion for 45 additional weeks. Results: Differences in point-prevalence abstinence rates between men (61.8%) and women (55.6%) in open-label bupropion (Week 7) were not significant. In the RP-phase Week 52, continuous abstinence rates for men and women were 37.8% and 36.4% (bupropion) and 36.6% and 29.9% (placebo), respectively; point-prevalence abstinence rates for men and women were 54.1% and 55.9% (bupropion) and 42.9% and 41.3% (placebo), respectively. Abstinence rates and time to relapse were superior for both men and women who received longer treatment. Gender differences within treatment groups were not significant. Median time to relapse was equal for men and women within each treatment group: Week 32 for bupropion and Week 20 for placebo.Conclusions: Our data suggest that bupropion is a promising pharmacotherapy for preventing relapse, particularly for women.

UR - http://www.scopus.com/inward/record.url?scp=0036231902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036231902&partnerID=8YFLogxK

U2 - 10.1016/S0749-3797(02)00419-1

DO - 10.1016/S0749-3797(02)00419-1

M3 - Article

C2 - 11988379

AN - SCOPUS:0036231902

VL - 22

SP - 234

EP - 239

JO - American Journal of Preventive Medicine

JF - American Journal of Preventive Medicine

SN - 0749-3797

IS - 4

ER -